Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
STAT13d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
Medscape23y
HumaPen Ergo®: A New 3.0ml Reusable Insulin Pen: Evaluation of Patient Acceptability
Objective: To assess the functionality and patient acceptability of HumaPen Ergo ®, a new 3.0ml reusable insulin pen. Design: Patients trialled HumaPen Ergo ® (Eli Lilly) over 5 to 7 weeks and ...
Future Market Insights9d
Global Disposable Pen Injectors Market to Reach USD 54.4 Billion by 2033 at a CAGR of 7.9%
In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...